CA2566793C - A novel dosage form - Google Patents

A novel dosage form Download PDF

Info

Publication number
CA2566793C
CA2566793C CA2566793A CA2566793A CA2566793C CA 2566793 C CA2566793 C CA 2566793C CA 2566793 A CA2566793 A CA 2566793A CA 2566793 A CA2566793 A CA 2566793A CA 2566793 C CA2566793 C CA 2566793C
Authority
CA
Canada
Prior art keywords
blend
sodium
vehicle according
agents
spoon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2566793A
Other languages
English (en)
French (fr)
Other versions
CA2566793A1 (en
Inventor
Daniel Bar-Shalom
Lillian Slot
Gina Fischer
Pernille Hoyrup Hemmingsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adare Pharma Solutions Inc
Original Assignee
Egalet Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Egalet Ltd filed Critical Egalet Ltd
Publication of CA2566793A1 publication Critical patent/CA2566793A1/en
Application granted granted Critical
Publication of CA2566793C publication Critical patent/CA2566793C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
    • A61J7/0015—Devices specially adapted for taking medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
    • A61J7/0015—Devices specially adapted for taking medicines
    • A61J7/0023—Spoons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
    • A61J7/0015—Devices specially adapted for taking medicines
    • A61J7/0046—Cups, bottles or bags
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Jellies, Jams, And Syrups (AREA)
CA2566793A 2004-05-11 2005-05-11 A novel dosage form Expired - Lifetime CA2566793C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200400755 2004-05-11
DKPA200400755 2004-05-11
PCT/DK2005/000317 WO2005107713A2 (en) 2004-05-11 2005-05-11 Swellable dosage form comprising gellan gum

Publications (2)

Publication Number Publication Date
CA2566793A1 CA2566793A1 (en) 2005-11-17
CA2566793C true CA2566793C (en) 2013-07-16

Family

ID=34967246

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2566793A Expired - Lifetime CA2566793C (en) 2004-05-11 2005-05-11 A novel dosage form

Country Status (8)

Country Link
US (2) US8383154B2 (https=)
EP (2) EP1758557B1 (https=)
JP (1) JP5154924B2 (https=)
AT (1) ATE516019T1 (https=)
CA (1) CA2566793C (https=)
DK (2) DK1758557T3 (https=)
ES (2) ES2517244T3 (https=)
WO (1) WO2005107713A2 (https=)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
EP1429744A1 (en) 2001-09-21 2004-06-23 Egalet A/S Morphine polymer release system
US20040234602A1 (en) 2001-09-21 2004-11-25 Gina Fischer Polymer release system
WO2004084868A1 (en) 2003-03-26 2004-10-07 Egalet A/S Morphine controlled release system
US7985418B2 (en) 2004-11-01 2011-07-26 Genzyme Corporation Aliphatic amine polymer salts for tableting
US20060275366A1 (en) * 2005-06-02 2006-12-07 Schering Corporation Controlled-release formulation
EP3000460A1 (en) * 2005-09-15 2016-03-30 Genzyme Corporation Sachet formulation for amine polymers
WO2007034287A2 (en) * 2005-09-19 2007-03-29 University Of The Witwatersrand, Johannesburg Oramucosal pharmaceutical dosage form
EP2104493A2 (en) * 2007-01-16 2009-09-30 Egalet A/S Use of i) a polyglycol and n) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
US8563066B2 (en) * 2007-12-17 2013-10-22 New World Pharmaceuticals, Llc Sustained release of nutrients in vivo
CN102014973A (zh) 2008-02-29 2011-04-13 弗罗桑医疗设备公司 用于促进止血和/或伤口愈合的装置
US9237972B2 (en) * 2008-12-16 2016-01-19 Kimberly-Clark Worldwide, Inc. Liquid surfactant compositions that adhere to surfaces and solidify and swell in the presence of water and articles using the same
EP2208493A1 (en) * 2009-01-15 2010-07-21 Sandoz AG Method and device for oral application of a composition
EP2389169A1 (en) * 2009-01-26 2011-11-30 Egalet A/S Controlled release formulations with continuous efficacy
CA2751667C (en) 2009-02-06 2016-12-13 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
CA2751627A1 (en) 2009-02-06 2010-08-12 Egalet Ltd. Pharmaceutical compositions resistant to abuse
CN102348457A (zh) 2009-03-11 2012-02-08 奥默罗斯公司 预防和治疗成瘾的组合物和方法
NZ597283A (en) 2009-06-24 2013-07-26 Egalet Ltd Controlled release formulations
FR2955252B1 (fr) * 2010-01-21 2012-03-23 Patrick Lesage Materiau d'insertion destine a elargir le sillon gingival
JP2013522246A (ja) 2010-03-15 2013-06-13 フェロサン メディカル デバイシーズ エイ／エス 止血および／または創傷治癒を促進するための方法
WO2012037117A1 (en) 2010-09-13 2012-03-22 Bev-Rx, Inc. Aqueous drug delivery system comprising off - flavor masking agent
US9132291B2 (en) 2010-10-05 2015-09-15 Dfb Technology, Ltd. Water-in-oil emulsion compositions containing gellan gum for topical delivery of active ingredients to the skin or mucosa
US8691275B2 (en) * 2011-01-28 2014-04-08 Zx Pharma, Llc Controlled-release melatonin compositions and related methods
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
US8911780B2 (en) 2011-02-11 2014-12-16 Zx Pharma, Llc Multiparticulate L-menthol formulations and related methods
US8808736B2 (en) 2011-02-11 2014-08-19 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
AU2012214553B2 (en) 2011-02-11 2015-07-09 Sociétés des Produits Nestlé S.A. Multiparticulate L-menthol formulations and related methods
JP5226097B2 (ja) * 2011-03-30 2013-07-03 株式会社ファンケル サプリメントを内包する蓋体とサプリメント分散媒を充填したボトルからなるボトル入り飲料
US9119793B1 (en) 2011-06-28 2015-09-01 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for doxycycline
US8898912B2 (en) * 2011-08-29 2014-12-02 Adam Leffler Spoon delivery device
CA2852447A1 (en) * 2011-10-19 2013-04-25 R.P. Scherer Technologies, Llc Two phase pharmaceutical delivery system
WO2013095215A1 (en) * 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
RU2657955C2 (ru) 2012-03-06 2018-06-18 Ферросан Медикал Дивайсиз А/С Контейнер под давлением, содержащий гемостатическую пасту
US9452135B2 (en) 2012-03-20 2016-09-27 Particle Dynamics International, Llc Gelling agent-based dosage form
WO2013169925A1 (en) * 2012-05-08 2013-11-14 Metronomx Novel formulations of nitrofurans including nifurtimox with enhanced activity with lower toxicity
EP2977066A3 (en) 2012-06-12 2016-07-27 Ferrosan Medical Devices A/S Dry haemostatic composition
AU2013285988A1 (en) 2012-07-06 2015-02-12 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
EP2934422A4 (en) * 2012-12-23 2016-07-20 Vadim Zelikman RUBBER SUPPORT FOR A MEDICAMENT, MEDIUM AND METHOD
US10842802B2 (en) 2013-03-15 2020-11-24 Medicis Pharmaceutical Corporation Controlled release pharmaceutical dosage forms
ES2706152T3 (es) 2013-04-23 2019-03-27 Zx Pharma Llc Composición entérica de múltiples partículas revestida con subrevestimiento proteico
AU2014283170B2 (en) 2013-06-21 2017-11-02 Ferrosan Medical Devices A/S Vacuum expanded dry composition and syringe for retaining same
CN105451723A (zh) * 2013-06-26 2016-03-30 爱荷华大学研究基金会 经口药物递送装置和其使用方法
JP6489485B2 (ja) 2013-12-11 2019-03-27 フェロサン メディカル デバイシーズ エイ／エス 押し出し増強因子を含んでいる乾燥組成物
SI3105218T1 (sl) 2014-02-13 2019-11-29 Incyte Corp Ciklopropilamini kot inhibitorji LSD1
MX373103B (es) 2014-02-13 2020-04-17 Incyte Holdings Corp Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1).
CA2943422C (en) * 2014-04-29 2020-03-10 The Procter & Gamble Company Bismuth-containing liquid pharmaceutical suspensions
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
CN105560281A (zh) * 2014-10-08 2016-05-11 华仁药业股份有限公司 一种混合糖电解质注射液及其制备方法
AU2015333206B2 (en) 2014-10-13 2019-07-11 Ferrosan Medical Devices A/S. Dry composition for use in haemostasis and wound healing
RU2705905C2 (ru) 2014-12-24 2019-11-12 Ферросан Медикал Дивайсиз А/С Шприц для удерживания и смешивания первого и второго веществ
US10792301B2 (en) * 2015-02-13 2020-10-06 The University Of Toledo Therapeutic polysaccharide midi-GAGR and related materials and methods
EP3277689B1 (en) 2015-04-03 2019-09-04 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
WO2016174664A1 (en) 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
JO3456B1 (ar) 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات
GR1008819B (el) 2015-05-22 2016-08-01 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα που περιλαμβανει ατομοξετινη και μεθοδος παρασκευης αυτου
CN107771093B (zh) 2015-07-03 2021-06-15 弗罗桑医疗设备公司 用于混合两种组分和用于在存储条件下保持真空的注射器
LT3334709T (lt) 2015-08-12 2025-03-10 Incyte Holdings Corporation Lsd1 inhibitoriaus druskos
KR20190008265A (ko) 2016-05-06 2019-01-23 피지션즈 씰, 엘엘씨 발레리안 조성물 및 관련 방법
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US10806789B2 (en) 2017-05-12 2020-10-20 The LIV Group Inc. Composition for enhanced absorption of supplements
US11801324B2 (en) 2018-05-09 2023-10-31 Ferrosan Medical Devices A/S Method for preparing a haemostatic composition
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
EP3699223A1 (de) * 2019-02-19 2020-08-26 LANXESS Deutschland GmbH Inline ultraschallkontrolle zur detektion des anvernetzens einer kautschukmischung bei der in situ silanisierung von hellen füllstoffen
MX2022005050A (es) * 2019-10-28 2022-07-04 Scherer Technologies Llc R P Cápsulas de gelatina blanda de liberación retardada en entorno de ph más alto.
JP7792917B2 (ja) * 2020-07-10 2025-12-26 アデア ファーマシューティカルズ，インコーポレイテッド 膨潤性経口医薬組成物
FR3119315B1 (fr) * 2021-02-02 2022-12-30 Virbac « gel diffuseur de pheromones »
US20240197635A1 (en) * 2021-03-03 2024-06-20 Veramorph Llc Dissociating polymer matrix compositions of fulvestrant and methods of their making and use
EP4392044A4 (en) * 2021-09-09 2025-01-22 Junion Labs Pte. Ltd. SUPERABSORBENT HYDROGELS WITH LIPASE INHIBITOR
US20260092128A1 (en) * 2022-09-25 2026-04-02 Albert Ludwigs University Of Freiburg Marine polysaccharide networks
AU2023366929A1 (en) 2022-10-25 2025-05-08 Veradermics, Incorporated Compositions and methods of use for modified release minoxidil
CN115566270B (zh) * 2022-11-02 2026-03-27 鹰潭耀宁新能源科技有限公司 一种锂离子电池用电解质及其制备方法
CN116449023B (zh) * 2023-04-10 2024-07-12 浙江伊利康生物技术有限公司 一种血清淀粉样蛋白a检测试剂盒及其制备方法
GB2630304A (en) * 2023-05-22 2024-11-27 Gelteq Ltd Pharmaceutical formulations
CN121793948A (zh) 2023-09-01 2026-04-03 豪夫迈·罗氏有限公司 用于制备半固体组合物的新颖方法及其用途
WO2025191578A1 (en) * 2024-03-14 2025-09-18 Softgel Healthcare Private Limited Gummesule dosage form for the improvement of bioavailability and enhanced patient compliance
DE102024111019A1 (de) 2024-04-19 2025-10-23 Gelita Ag Gelmasse zur Herstellung von Weichkapseln oder Filmen, deren Verwendung und Herstellungsverfahren
CN119756467B (zh) * 2024-12-17 2025-10-03 重庆理工大学 一种温湿度原位检测传感器、湿度传感器制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994260A (en) 1982-05-28 1991-02-19 Astra Lakemedel Aktiebolag Pharmaceutical mixture
US4590075A (en) 1984-08-27 1986-05-20 Warner-Lambert Company Elastomer encapsulation of flavors and sweeteners, long lasting flavored chewing gum compositions based thereon and process of preparation
US4824681A (en) 1986-12-19 1989-04-25 Warner-Lambert Company Encapsulated sweetener composition for use with chewing gum and edible products
GB8702411D0 (en) 1987-02-03 1987-03-11 Zyma Sa Swellable pellets
US5234957A (en) 1991-02-27 1993-08-10 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
MX9102619A (es) 1990-12-17 1992-06-01 Redding Bruce K Metodo y aparato para revestir materiales.
US5126151A (en) 1991-01-24 1992-06-30 Warner-Lambert Company Encapsulation matrix
US5881926A (en) 1993-03-11 1999-03-16 Taro Pharmaceutical Industries, Ltd. Pharmaceutical compositions in semisolid form and a device for administration thereof
IL108366A (en) * 1993-03-11 1999-11-30 Taro Vit Ind Ltd Semi-solid pharmaceutical compounds and a device for their use
ATE260646T1 (de) * 1996-04-16 2004-03-15 Novartis Consumer Health Sa Schnell zerfallende orale dosierungsform
CA2262595C (en) * 1996-08-15 2005-10-18 Losan Pharma Gmbh Easy to swallow oral medicament composition
AU5453198A (en) * 1996-11-29 1998-06-22 Monsanto Company Lubricious self-standing (intact) gel for oral delivery of biologically-active ingredients
US6326028B1 (en) * 1997-10-31 2001-12-04 Monsanto Company Alginate and gellan gum as tablet coating
JP3524359B2 (ja) 1997-12-26 2004-05-10 伊那食品工業株式会社 咀嚼・嚥下困難者用の摂食補助用糊料
US6071523A (en) * 1998-06-03 2000-06-06 Taro Pharmaceuticals Industries, Ltd. Spill resistant pharmaceutical compositions in semi-solid form
SK284948B6 (sk) 2000-04-06 2006-03-02 Zentiva, A. S. Liečivý prípravok s obsahom vápnika alebo zmesi vápnika a vitamínu D, alebo zmesi vápnika a horčíka v novej liekovej forme
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6474418B2 (en) 2000-12-07 2002-11-05 Frank's International, Inc. Wellbore fluid recovery system and method
CA2366327A1 (en) 2000-12-21 2002-06-21 Oscar M. Bassinson Personal medication dispensing card
US6589955B2 (en) 2001-06-20 2003-07-08 Bristol-Myers Squibb Company Pediatric formulation of gatifloxacin
CA2461616A1 (en) * 2001-09-28 2003-04-03 Mcneil-Ppc, Inc. Composite dosage forms having an inlaid portion
CZ12993U1 (cs) 2001-11-23 2003-02-10 Glaxo Group Limited Farmaceutický prostředek
JP3835544B2 (ja) * 2002-09-10 2006-10-18 明治乳業株式会社 ゼリー乾燥物
CN1780880B (zh) 2003-04-25 2010-04-28 雷克特本克斯尔保健(英国)有限公司 可增稠的组合物
WO2005007074A2 (en) * 2003-07-21 2005-01-27 Bio-Dar Ltd. Gellan gum based oral controlled release dosage forms- a novel platform technology for gastric retention
US9109434B2 (en) 2013-06-09 2015-08-18 Schlumberger Technology Corporation System and method for estimating oil formation volume factor downhole

Also Published As

Publication number Publication date
ES2517244T3 (es) 2014-11-03
US20080299199A1 (en) 2008-12-04
US8383155B2 (en) 2013-02-26
CA2566793A1 (en) 2005-11-17
EP1758557B1 (en) 2011-07-13
EP1758557A2 (en) 2007-03-07
EP2258349A2 (en) 2010-12-08
WO2005107713A2 (en) 2005-11-17
EP2258349B1 (en) 2014-07-16
US20120039969A1 (en) 2012-02-16
DK2258349T3 (da) 2014-10-13
EP2258349A3 (en) 2012-04-04
JP2007537169A (ja) 2007-12-20
ES2370729T3 (es) 2011-12-22
DK1758557T3 (da) 2011-10-24
US8383154B2 (en) 2013-02-26
WO2005107713A3 (en) 2006-05-18
JP5154924B2 (ja) 2013-02-27
ATE516019T1 (de) 2011-07-15

Similar Documents

Publication Publication Date Title
CA2566793C (en) A novel dosage form
CA2890567C (en) Chewable gelled emulsions
GB2349570A (en) Compositions for treatment of disorders of the oesophagus
EA021784B1 (ru) Фармацевтические композиции с длительным высвобождением
WO2011008760A1 (en) Rapid melt compositions and methods of making same
JP6664080B2 (ja) プレガバリン徐放性製剤
WO2007113454A1 (en) Particulate compositions comprising alginate and/or alginic acid
CA2661575C (en) Pharmaceutical compositions easy to swallow, not causing any unpleasant oral sensation and comprising particles with an active principle
WO2009055925A1 (en) Enhanced nsaid formulations
JP4965096B2 (ja) 圧縮成型製剤
US8889184B2 (en) Particulate form of a pharmaceutical composition which is easy to swallow
JP2019147831A (ja) ミソプロストール分散性錠剤
TWI703989B (zh) 口腔內保持型崩解性固形製劑、其製造方法、及用於該製造方法之粉體組成物
JP2008133294A (ja) 口腔内崩壊型錠剤
AU2006341307B2 (en) Particulate compositions comprising alginate and/or alginic acid
JP2010159289A (ja) 圧縮成形製剤およびその製造方法
JP2008214325A (ja) 固形製剤

Legal Events

Date Code Title Description
EEER Examination request
H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20251106

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20251113